May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Bilateral Vitreous and Subretinal Hemorrhages During Treatment with Activated Protein C
Author Affiliations & Notes
  • B. Lujan
    Ophthalmology, UCSF, San Francisco, CA
  • D. Wilson
    Ophthalmology, Kaiser Permanente, Vallejo, CA
  • R. Vora
    Ophthalmology, UCSF, San Francisco, CA
  • D. Schwartz
    Ophthalmology, UCSF, San Francisco, CA
  • Footnotes
    Commercial Relationships  B. Lujan, None; D. Wilson, None; R. Vora, None; D. Schwartz, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 2070. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      B. Lujan, D. Wilson, R. Vora, D. Schwartz; Bilateral Vitreous and Subretinal Hemorrhages During Treatment with Activated Protein C . Invest. Ophthalmol. Vis. Sci. 2004;45(13):2070.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To describe the occurrence of severe intraocular hemorrhage in a patient treated for sepsis with Recombinant Human Activated Protein C (RH–APC). Methods: Retrospective chart review, and review of the literature regarding clinical experience with RH–APC. Results:The majority of patients with severe sepsis demonstrate markedly diminished levels of APC, a key regulator of clotting homeostasis. In vitro data have demonstrated that APC inhibits thrombosis, promotes fibrinolysis, downregulates inflammation, and inhibits endothelial cell apoptosis. In severe sepsis, the factors responsible for activating Protein C are rapidly consumed resulting in disseminated thrombosis and multi–organ system failure. RH–APC has recently been shown in a randomized, double–blind, placebo controlled trial, to significantly reduce mortality from severe sepsis, and is finding a more prominent role in critical care medicine. The reported incidence of serious bleeding while being treated with RH–APC was slightly higher in the treatment group (3.5 percent vs. 2.0 percent, P=0.06). We describe a patient who survived sepsis and disseminated intravascular coagulation, but developed bilateral vitreous hemorrhages and a hemorrhagic retinal detachment while being treated with RH–APC. Conclusions: The medical treatment of sepsis associated with acute organ dysfunction remains one of the most difficult challenges in critical care medicine. Despite marked advances in technology, the rate of death from severe sepsis remains 30 to 50 percent. RH–APC has been recently introduced as a novel treatment modality. Bilateral vitreous and subretinal hemorrhages have not been previously described as a complication of this therapy. RH–APC is being used more frequently to combat mortality in sepsis, and we would like to alert the ophthalmic community regarding a blinding side effect of this medication.

Keywords: retinal detachment • pharmacology • vitreous 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×